Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine...
-
Pharmala announces a newly signed contract to supply a clinical trial, and the fulfillment of a previously announced trial.
-
PharmAla to receive clinical trial data from harvard-affiliated hospital in exchange for a drug donation
-
PharmAla to supply University of Amsterdam with LaNeo MDMA for a clinical trial, generating new stability data for blister packs in the process
-
NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine...
-
NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine...
-
NEW YORK, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine...
-
PharmAla announces the resignation of Dr. Malik Slassi and the appointment of Mr Lennie Ryer to its board.
-
WASHINGTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- With the United States in a pivotal election year, the Multidisciplinary Association for Psychedelic Studies (MAPS) released its Policy Guidebook, a...
-
Eleusis, the world’s first legal luxury psychedelic immersion, using DMTx protocols, will officially debut in March 2026.